Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경진 | * |
dc.date.accessioned | 2022-06-02T16:30:56Z | - |
dc.date.available | 2022-06-02T16:30:56Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 1475-2840 | * |
dc.identifier.other | OAK-31510 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/261156 | - |
dc.description.abstract | Background: Statin treatment increases the risk of new-onset diabetes mellitus (NODM); however, data directly comparing the risk of NODM among individual statins is limited. We compared the risk of NODM between patients using pitavastatin and atorvastatin or rosuvastatin using reliable, large-scale data. Methods: Data of electronic health records from ten hospitals converted to the Observational Medical Outcomes Partnership Common Data Model (n = 14,605,368 patients) were used to identify new users of pitavastatin, atorvastatin, or rosuvastatin (atorvastatin + rosuvastatin) for ≥ 180 days without a previous history of diabetes or HbA1c level ≥ 5.7%. We conducted a cohort study using Cox regression analysis to examine the hazard ratio (HR) of NODM after propensity score matching (PSM) and then performed an aggregate meta-analysis of the HR. Results: After 1:2 PSM, 10,238 new pitavastatin users (15,998 person-years of follow-up) and 18,605 atorvastatin + rosuvastatin users (33,477 person-years of follow-up) were pooled from 10 databases. The meta-analysis of the HRs demonstrated that pitavastatin resulted in a significantly reduced risk of NODM than atorvastatin + rosuvastatin (HR 0.72; 95% CI 0.59–0.87). In sub-analysis, pitavastatin was associated with a lower risk of NODM than atorvastatin or rosuvastatin after 1:1 PSM (HR 0.69; CI 0.54–0.88 and HR 0.74; CI 0.55–0.99, respectively). A consistently low risk of NODM in pitavastatin users was observed when compared with low-to-moderate-intensity atorvastatin + rosuvastatin users (HR 0.78; CI 0.62–0.98). Conclusions: In this retrospective, multicenter active-comparator, new-user, cohort study, pitavastatin reduced the risk of NODM compared with atorvastatin or rosuvastatin. © 2022, The Author(s). | * |
dc.language | English | * |
dc.publisher | BioMed Central Ltd | * |
dc.subject | Common data model | * |
dc.subject | Diabetes mellitus | * |
dc.subject | Pitavastatin | * |
dc.subject | Statin | * |
dc.title | Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 21 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | Cardiovascular Diabetology | * |
dc.identifier.doi | 10.1186/s12933-022-01524-6 | * |
dc.identifier.wosid | WOS:000799241900001 | * |
dc.identifier.scopusid | 2-s2.0-85130445570 | * |
dc.author.google | Seo W.-W. | * |
dc.author.google | Seo S.I. | * |
dc.author.google | Kim Y. | * |
dc.author.google | Yoo J.J. | * |
dc.author.google | Shin W.G. | * |
dc.author.google | Kim J. | * |
dc.author.google | You S.C. | * |
dc.author.google | Park R.W. | * |
dc.author.google | Park Y.M. | * |
dc.author.google | Kim K.-J. | * |
dc.author.google | Rhee S.Y. | * |
dc.author.google | Park M. | * |
dc.author.google | Jin E.-S. | * |
dc.author.google | Kim S.E. | * |
dc.contributor.scopusid | 김경진(57190021870) | * |
dc.date.modifydate | 20240426120924 | * |